https://assets.capyfin.com/instruments/678fdc13234e27009c5d5879.png avatar
DaVita
🇺🇸 NYSE:DVA
View Company
OverviewEarningsDividends
•
Jun 30, 2021

DaVita Q2 2021 Earnings Report

DaVita's financial performance was strong in Q2 2021, with significant growth in earnings per share and advancements in integrated kidney care capabilities.

Key Takeaways

DaVita Inc. reported a strong quarter with diluted earnings per share from continuing operations increasing by 63.0% year-over-year. The company saw progress in combating COVID-19 and accelerated investments in integrated kidney care capabilities, growing the number of patients under value-based care arrangements to approximately 10% of the U.S. dialysis patient census.

Consolidated revenues reached $2.917 billion.

Operating income amounted to $490 million.

Diluted earnings per share was $2.64.

Operating cash flow and free cash flow from continuing operations were $680 million and $503 million, respectively.

Total Revenue
$2.92B
Previous year: $2.88B
+1.3%
EPS
$2.64
Previous year: $1.95
+35.4%
US Dialysis Treatments
7.41M
Previous year: 7.57M
-2.1%
US Avg Treatments per day
95.05K
Previous year: 97.06K
-2.1%
US Revenue per Treatment
$360
Previous year: $352
+2.2%
Gross Profit
$951M
Previous year: $895M
+6.2%
Cash and Equivalents
$1.04B
Previous year: $2.93B
-64.4%
Free Cash Flow
$503M
Previous year: $507M
-0.8%
Total Assets
$17.8B
Previous year: $19.3B
-7.7%

DaVita

DaVita

DaVita Revenue by Segment

DaVita Revenue by Geographic Location

Forward Guidance

DaVita provided its 2021 financial outlook, with adjusted operating income expected to be between $1.8 billion and $1.875 billion, adjusted diluted net income from continuing operations per share attributable to DaVita Inc. between $8.80 and $9.40, and free cash flow from continuing operations between $1 billion and $1.2 billion.

Positive Outlook

  • Adjusted operating income is projected to be between $1,800 million and $1,875 million.
  • Adjusted diluted net income from continuing operations per share is expected to range from $8.80 to $9.40.
  • Free cash flow from continuing operations is anticipated to be between $1,000 million and $1,200 million.
  • The company is focused on growing its integrated kidney care business.
  • DaVita is actively managing its capital structure through stock repurchases.

Challenges Ahead

  • The widespread impact of the COVID-19 pandemic continues to generate significant risk and uncertainty.
  • Future results could vary materially from the guidance provided due to the pandemic.
  • Guidance excludes certain items, including foreign currency fluctuations, which may be significant.
  • There is continued downward pressure on average realized payment rates from commercial payor plans.
  • Healthcare reform and changes in legislation or regulations could reduce coverage or reimbursement rates.

Revenue & Expenses

Visualization of income flow from segment revenue to net income

Company Overview

Full financial data and analysis

View DaVita